Consensus expectations for the genomic diagnostics leader are $111.01 million in revenue and a $0.19 loss per share, with the stock currently trading at $68.93 compared to an average analyst price target of $87.43.
Investors are primarily focused on exome and genome testing volumes, with management providing Q2 2026 guidance of approximately 30,000 tests to confirm demand stability.
This report follows a turbulent first quarter where the company lowered its full-year 2026 revenue outlook to $475-$490 million due to reimbursement headwinds and market dynamics. Additionally, market participants are weighing the impact of ongoing legal developments surrounding the Fabric Genomics acquisition and its effect on long-term margin recovery.